Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

00 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety InformationDo not exceed the maximum recommended daily dose of acetaminophen. Administration of acetaminophen by any route in doses higher than recommended may result in hepatic injury, including the risk of severe hepatotoxicity and death. OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. OFIRMEV should be administered only as a 15-minute intravenous infusion. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur. Do not use in patients with acetaminophen allergy. The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated for post-surgical pain.

For more information, please see the complete OFIRME
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Whitehouse Laboratories is pleased to ... County (New Jersey) Chamber of Commerce as a ... organization in the North Jersey area, offers Whitehouse ... key clients in the pharmaceutical and biotechnology areas ... Membership enables Whitehouse Laboratories a higher level of ...
(Date:11/26/2014)... 2014 The Pittcon marketing department is ... and exposition mobile app, Pittcon 2015 ... the App Store for iOS and Android devices and ... before, during and after the event. It acts as ... companies, technical sessions, Conferee Networking sessions and short courses. ...
(Date:11/26/2014)... WILMINGTON, DE (PRWEB) November 26, 2014 ... MPN Heroes recognition reception on December 5, 2014, in ... annual meeting. The MPN Heroes event will honor clinicians, ... the field of myeloproliferative neoplasms (MPNs). , Special ... will discuss his family's cancer journey at the reception. ...
(Date:11/26/2014)... novembre 2014 /PRNewswrie/ -- Theravalues Corporation annuncia con orgoglio ... in occasione di Hi Europe 2014 (dal 2 al ... Si tratta della curcumina con la maggiore biodisponibilità di ... e ingredienti approvati dalle norme europee. La ... pianta curcumina ( Curcuma longa ) che è stata ...
Breaking Biology Technology:Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Pittcon Releases 2015 Mobile App 2CURE Magazine and Incyte to Honor MPN Heroes 2CURE Magazine and Incyte to Honor MPN Heroes 3CURE Magazine and Incyte to Honor MPN Heroes 4La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3
... With the advent of liquid chromatography/ mass spectrometry and information dependent ... characterise metabolites while to quantifying their parents during metabolic stability studies. ... Abstract , ... based on a triple quadrupole ion path and is capable of ...
... Characterization of nucleotide and nucleoside analogs from Taraxacum mongolicum, ... time using liquid chromatography tandem mass spectrometry (LC/MS/MS). The ... and nucleoside standards with product and precursor scans of ... be major active ingredients which have anti-Herpes simplex virus ...
... , ... Edman sequence analysis and electrospray tandem mass spectrometry provides accurate and detailed structural ... Purpose , ... peptides is greatly facilitated using a combination of the Procise cLC 492 sequencing ...
Cached Biology Technology:Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 2Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 3Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 5Isolation and Characterization of Anti-Viral Nucleoside Compounds from the Chinese Herb Taraxacum Mongolicum 2Isolation and Characterization of Anti-Viral Nucleoside Compounds from the Chinese Herb Taraxacum Mongolicum 3Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 2Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 3Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 4Efficient Primary Structure Elucidation of Disulfide-bridged Peptides 5
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
(Date:11/18/2014)... BOSTON , Nov. 17, 2014   ... HealthCare and EMC collaborate to develop The Partners ... , The Partners Data Lake will allow ... to improve diagnostics, treatment and the lives of ... support research and clinical activities across the Partners ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... CHAMPAIGN, Ill. By creating a model of the active ... University of Illinois have described a catalyst that acts like ... work in a paper accepted for publication in the ... the journal,s Web site. , Scientists have long been puzzled ...
... to 500 million cases of malaria are diagnosed each ... prevent and treat malaria do exist, the demand for ... malaria parasites have developed a resistance to existing medications. ... of Medicine have discovered one way to stop malaria ...
... considered the one and only way biological traits could ... Not anymore. Increasingly, biologists are finding that non-genetic ... sometimes be passed on to offspringa phenomenon known as ... of The Quarterly Review of Biology lists ...
Cached Biology News:New lead on malaria treatment 2100 reasons to change the way we think about genetics 2100 reasons to change the way we think about genetics 3